|
Hepatitis C
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus NS5A inhibits mixed lineage kinase 3 to block apoptosis.
|
23857585 |
2013 |
|
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
Mixed lineage kinase 3 connects reactive oxygen species to c-Jun NH2-terminal kinase-induced mitochondrial apoptosis in genipin-treated PC3 human prostate cancer cells.
|
17707342 |
2007 |
|
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Mixed lineage kinase 3 connects reactive oxygen species to c-Jun NH2-terminal kinase-induced mitochondrial apoptosis in genipin-treated PC3 human prostate cancer cells.
|
17707342 |
2007 |
|
Carcinoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
MLK3 mutations were significantly associated with MSI phenotype in primary tumours (P = 0.0005), occurring in 21% of the MSI carcinomas.
|
19955118 |
2010 |
|
Delirium, Dementia, Amnestic, Cognitive Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
MLK3 activation is associated with many of the pathologic hallmarks of HAND (Bodner et al., 2002, 2004; Sui et al., 2006) and therefore represents a prime target for adjunctive therapy based on small-molecule kinase inhibition.
|
23761895 |
2013 |
|
Neurocognitive Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
MLK3 activation is associated with many of the pathologic hallmarks of HAND (Bodner et al., 2002, 2004; Sui et al., 2006) and therefore represents a prime target for adjunctive therapy based on small-molecule kinase inhibition.
|
23761895 |
2013 |
|
Malignant neoplasm of gastrointestinal tract
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
MLK3 gene mutations were described to occur in about 20% of microsatellite unstable gastrointestinal cancers and to harbor oncogenic activity.
|
24628919 |
2014 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells.
|
26138442 |
2016 |
|
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
MLK3 silencing or MLK inhibition blocks EGF-induced JNK activation, suggesting that MLK3-JNK signaling promotes invasion of GBM cells.
|
28487380 |
2017 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.
|
28604765 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.
|
28604765 |
2017 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Mixed-lineage kinase 3 (MLK3), a mitogen-activated protein kinase kinase kinase (MAP3K), has critical roles in metastasis of triple-negative breast cancer (TNBC), in part by regulating paxillin phosphorylation and focal adhesion turnover.
|
28604765 |
2017 |
|
Tumor Cell Invasion
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
MLK3-induced ER+ BC cell invasion is abrogated by FRA-1 silencing, demonstrating that MLK3 drives invasion through FRA-1.
|
28604765 |
2017 |
|
Tumor Cell Invasion
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
Mixed Lineage Kinase 3 (MLK3), a member of the MLK subfamily of protein kinases, is a mitogen-activated protein (MAP) kinase kinase kinase (MAP3K) that activates MAPK signalling pathways and regulates cellular responses such as proliferation, invasion and apoptosis.
|
28757353 |
2017 |
|
Nonalcoholic Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis.
|
28768902 |
2017 |
|
Tumor Cell Invasion
|
0.080 |
PosttranslationalModification
|
phenotype |
BEFREE |
MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells.
|
29084209 |
2018 |
|
Left Ventricular Hypertrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
MAP3K11 is related to the JNK pathway and is a pro-apoptotic kinase that plays an important role in the induction of cardiomyocyte apoptosis in various pathologies, including LVH.
|
29506515 |
2018 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Mixed lineage kinase 3 (MLK3), a MAP3K member has been envisioned as a viable drug target in cancer, yet its detailed function and signaling is not fully elucidated.
|
30664689 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Mixed lineage kinase 3 (MLK3), a MAP3K member has been envisioned as a viable drug target in cancer, yet its detailed function and signaling is not fully elucidated.
|
30664689 |
2019 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Mixed-lineage kinase 3 (MLK3), the mitogen-activated protein kinase kinase kinase (MAP3K), has been recognized as a player in tumorigenesis and oncogenic signalling, yet its detailed functions and signalling in cervical cancer have not been fully elucidated.
|
31192472 |
2019 |
|
Periodontal Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Ptk1 reciprocally phosphorylated Php1 on tyrosine residues 159 and 161, which independently impacted phosphatase activity.Loss of Php1 rendered <i>P. gingivalis</i> nonvirulent in an animal model of periodontal disease.
|
31551334 |
2019 |
|
Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
A novel lnc-PCF promotes the proliferation of TGF-β1-activated epithelial cells by targeting miR-344a-5p to regulate map3k11 in pulmonary fibrosis.
|
29072702 |
2017 |
|
Neurodegenerative Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Aberrant activation of MLK3 has been implicated in neurodegenerative diseases.
|
17711861 |
2007 |
|
Delirium, Dementia, Amnestic, Cognitive Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Anthocyanins attenuate neuroinflammation through the suppression of MLK3 activation in a mouse model of perioperative neurocognitive disorders.
|
31654642 |
2020 |
|
Neurocognitive Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Anthocyanins attenuate neuroinflammation through the suppression of MLK3 activation in a mouse model of perioperative neurocognitive disorders.
|
31654642 |
2020 |